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Abstract
WHO 2016 classified glioblastomas into IDH-mutant and IDH-wildtype with the former having a better prognosis but there
was no study on IDH-mutant primary glioblastomas only, as previous series included secondary glioblastomas. We recruited
a series of 67 IDH-mutant primary glioblastomas/astrocytoma IV without a prior low-grade astrocytoma and examined them
using DNA-methylation profiling, targeted sequencing, RNA sequencing and TERT promoter sequencing, and correlated the
molecular findings with clinical parameters. The median OS of 39.4 months of 64 cases and PFS of 25.9 months of 57 cases
were better than the survival data of IDH-wildtype glioblastomas and IDH-mutant secondary glioblastomas retrieved from
datasets. The molecular features often seen in glioblastomas, such as EGFR amplification, combined +7/−10, and TERT
promoter mutations were only observed in 6/53 (11.3%), 4/53 (7.5%), and 2/67 (3.0%) cases, respectively, and gene fusions
were found only in two cases. The main mechanism for telomere maintenance appeared to be alternative lengthening of
telomeres as ATRX mutation was found in 34/53 (64.2%) cases. In t-SNE analyses of DNA-methylation profiles, with an
exceptional of one case, a majority of our cases clustered to IDH-mutant high-grade astrocytoma subclass (40/53; 75.5%)
and the rest to IDH-mutant astrocytoma subclass (12/53; 22.6%). The latter was also enriched with G-CIMP high cases (12/
12; 100%). G-CIMP-high status and MGMT promoter methylation were independent good prognosticators for OS (p=
0.022 and p= 0.002, respectively) and TP53 mutation was an independent poor prognosticator (p= 0.013) when correlated
with other clinical parameters. Homozygous deletion of CDKN2A/B was not correlated with OS (p= 0.197) and PFS (p=
0.278). PDGFRA amplification or mutation was found in 16/59 (27.1%) of cases and was correlated with G-CIMP-low
status (p= 0.010). Aside from the three well-known pathways of pathogenesis in glioblastomas, chromatin modifying and
mismatch repair pathways were common aberrations (88.7% and 20.8%, respectively), the former due to high frequency of
ATRX involvement. We conclude that IDH-mutant primary glioblastomas have better prognosis than secondary
glioblastomas and have major molecular differences from other commoner glioblastomas. G-CIMP subgroups, MGMT
promoter methylation, and TP53 mutation are useful prognostic adjuncts.
Introduction
The WHO 2016 Classification of Tumours of the Central
Nervous System classified glioblastomas by the IDH status.
[1] IDH-wildtype glioblastomas make up the majority of the
tumours and have a poorer prognosis than IDH-mutant
glioblastomas. Secondary glioblastomas, which arise from a
previous low-grade astrocytoma, are regarded as mostly
IDH-mutant. Increasingly, IDH-mutant glioblastomas and
IDH-mutant low-grade astrocytomas have undergone scru-
tiny as only a small number of IDH-mutant glioblastomas
were evaluated for molecular pathology prior to the WHO
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2016 classification [2]. Since then, there have been three
sizeable series of IDH-mutant glioblastomas including ours
[3–5]. Two studies [3, 4] have characterized the cohort
more extensively and shown that IDH-mutant glioblastomas
are a more heterogenous group for risk than hitherto
thought, with some having a poor prognosis, especially
those with CDKN2A/B homozygous deletion. A few studies
have also identified homozygous deletion of CDKN2A/B,
alone or in combination with other biomarkers, as a poor
prognosticator in IDH-mutant histologically low-grade dif-
fuse astrocytomas [3, 6–10]. These studies prompted the
cIMPACT-NOW group to propose a replacement of the
term IDH-mutant glioblastoma with IDH-mutant astro-
cytoma, WHO Grade IV, and with CDKN2A/B homo-
zygous deletion being a diagnostic hallmark irrespective of
whether other features of malignancy in astrocytomas,
such as necrosis or endothelial proliferation, are present or
not [11].
In a large series of 188 secondary glioblastomas, Hu
et al. showed that only 67% of them were IDH-mutant and
their prognosis was seemingly not dissimilar to that of IDH-
wildtype glioblastomas [12]. By the same token, Miller
et al. showed that once IDH-mutant low-grade gliomas
progressed, presumably with many becoming high-grade
gliomas, clinical progression was rapid [13]. Hence, it
seems that IDH-mutant glioblastomas or IDH-mutant
astrocytoma, Grade IV, can be separated clinically into
primary and secondary IDH-mutant glioblastomas. Hu et al.
extensively evaluated the mutational landscape of second-
ary glioblastomas and identified MET-exon14 skipping
(METex14) as a novel therapeutic target [12]. In this paper,
we collected a cohort of 67 IDH-mutant primary glio-
blastomas and evaluated its molecular landscape by DNA-
methylation profiling, targeted sequencing, and RNA
sequencing, and in addition performed Sanger sequencing
for TERT promoter. We established G-CIMP status and
copy number alterations (CNA) for genes regarded as cri-
tical in the pathogenesis of glioblastomas. Finally, we cor-
related the molecular landscape with the clinical variables.




Tumour samples were retrieved from Prince of Wales
Hospital (Hong Kong, China), Hua Shan Hospital (Shang-
hai, China) and the First Affiliated Hospital of Zhengzhou
University (Zhengzhou, China) from 2008 onwards and
cases of primary IDH-mutant glioblastomas were selected.
They were from adult patients (>17 years old) with a
histological diagnosis of glioblastomas and with a clinical
history of <3 months [3] and there was no previous history
of a low grade astrocytoma. The cohort included 27 cases of
a previous study [4] but the secondary glioblastomas of that
series were excluded. Previous diagnostic workups of these
cases included Sanger sequencing for IDH1 and IDH2 and
they were shown to be IDH-mutant. Ethics approvals were
obtained from The Joint Chinese University of Hong
Kong–New Territories East Cluster Clinical Research Eth-
ics Committee, and the Ethics Committees of Huashan
Hospital, Shanghai and The First Affiliated Hospital of
Zhengzhou University, Zhengzhou. The study was per-
formed in accordance with the Declaration of Helsinki.
Hematoxylin-eosin stained sections were reviewed and the
diagnosis of glioblastoma was confirmed by three patholo-
gists (HKN, HC, WWW). The histological diagnoses were
as per WHO 2016 Classification [1]. Data on patient
demographics and therapeutic treatment were retrieved from
institutional paper and electronic records. Survival data
were obtained from follow-up clinic visits and direct contact
with patients or close relatives via phone.
IDH1, IDH2, and TERT promoter mutation analysis
Only samples with IDH1 or IDH2 mutation were included
in this study. IDH1/2 and TERT promoter mutation was
evaluated by Sanger sequencing. In brief, crude cell lysate
was prepared from formalin-fixed paraffin-embedded
(FFPE) sections accordingly [14]. DNA from the lysate was
amplified using forward primer (IDH1: 5′-CGGTCTTCAG
AGAAGCCATT-3′; IDH2 5′-AGCCCATCATCTGCAAA
AAC-3′; and, TERT 5′-GTCCTGCCCCTTCACCTT-3′),
reverse primer (IDH1: 5′-CACATTATTGCCAACATGA
C-3′; IDH2 5′-CTAGGCGAGGAGCTCCAGT-3′; and,
TERT 5′-CAGCGCTGCCTGAAACTC-3′), KAPA Robust
HotStart ReadyMix (Sigma)/KAPA HiFi HotStart Ready-
Mix (Sigma). Amplification was conducted on a thermal
cycler according to the manufacturer’s recommendation.
PCR products were visualized on electrophoresis gel,
cleaned with a spin column-based PCR product purification
kit (iNtRON Biotechnology) and sequenced with BigDye
Terminator Cycle Sequencing kit v1.1 (Life Technologies).
Illumina infinium methylationEPIC BeadChip array
FFPE sections were sent to Shanghai, China (Sinotech
Genomics Co., Ltd), where the DNA was extracted, bisul-
fite modified and subjected to DNA-methylation profiling
by EPIC Illumina Infinium Human (850k) Array following
the manufacture’s recommendation (Illumina). Unprocessed
IDAT files can be downloaded from http://www.acp.cuhk.
edu.hk/hkng. Background correction, global dye-bias nor-
malization, and calculation of DNA-methylation level were
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parts of EPIC array preprocessing, and were performed
according to the previous publications [15, 16]. G-CIMP
status were determined using a random forest (RF) machine
learning algorithm as described in previous publications
[15, 16]. The most variable probes were used to generate
t-SNE plot according to Capper et al. study [17]. The t-SNE
(t-distributed stochastic neighbour embedding) plot was
generated with Rtsne R package. The raw IDAT files were
uploaded to DKFZ ‘Classifier’ tool (https://www.molecula
rneuropathology.org) for supervised analysis using the RF
methylation class prediction algorithm [17]. MGMT pro-
moter methylation status was computed by DKFZ
‘Classifier’ tool.
Determination of copy number variations with EPIC
850k array
To determine copy number variations, probe-level signal
intensities were retrieved from the IDAT files and then
subjected to background correction and dye-bias normal-
ization. Probes targeting the sex chromosomes, containing
single-nucleotide polymorphisms, or mapping to multiple
locations in the human genome were excluded to avoid
inaccurate assessment. Two sets of 50 control samples
derived from male and female donors were used for nor-
malization [17]. Copy number variation analysis were per-
formed using the ‘conumee’ R package in Bioconductor
(http://www.bioconductor.org/packages/release/bioc/html/
conumee.html). A log2 ratio +0.35 was used as a cutoff for
amplification and a log2 ratio −0.415 was used for the
cutoff of homozygous losses [9].
GISTIC v2.0 analysis was conducted to identify sig-
nificantly recurrent copy number amplification and dele-
tions at arm-level and focal-level, defined as affected
regions spanning <50% of a chromosome arm [18, 19].
Targeted sequencing
DNA was obtained from FFPE sections using GeneRead
DNA FFPE kit (Qiagen). The quality and quantity of
extracted DNA were assessed by QIAseq DNA Quanti-
MIZE Assay (Qiagen). Samples that passed quality control
were subjected to library preparation with a custom QIAseq
Targeted DNA Panel, covering the coding exons of 74
genes altered in gliomas and other CNS tumours. The DNA
libraries were then further assessed for quality and quantity.
Sequencing of libraries passing quality control was per-
formed on MiSeq v3 (Illumina).
Paired-end reads were aligned to the hg19 (GRCh37)
build of the human reference genome with BWA-MEM
algorithm on GeneGlobe platform (Qiagen). Variants were
called using smCounter2 [20] and annotated using wAN-
NOVAR [21]. Variants with the following criteria were
excluded: not passing quality filters, with variant allele
fractions of <5%, with variant allele counts of <5, or with
minor allele frequencies of >1% in overall human population
or East Asians or documented in public databases (1000
Genomes, ExAc, gnomAD exome and genome databases).
RNA sequencing
RNA was extracted from FFPE sections using RNeasy
FFPE kit (Qiagen). RNA passing quality control examina-
tion was subjected to cDNA synthesis and molecular
barcode-indexed ligation library preparation. Target capture
was done using TruSight RNA Pan-Cancer Panel (Illu-
mina), which covered 1385 genes commonly involved in
cancer. Libraries were sequenced on MiSeq instrument
(Illumina).
Paired-end reads were aligned to human genome
assembly GRCh37 (hg19) and fusion genes were called
using the STAR aligner and STAR fusion caller [22, 23].
In-frame fusion genes with at least five junction reads were
further confirmed by conventional RT-PCR.
Statistical analysis
Statistical analysis was performed on IBM SPSS software
v22. Overall survival (OS) was defined as the period of time
between operation and death or the last follow-up.
Progression-free survival (PFS) was defined as the time
between operation and recurrence revealed by neuror-
adiological finding. Chi-square or Fisher’s test was applied
to determine correlation between molecular alterations and
clinical parameters and between different molecular altera-
tions. Survival curves were evaluated by the Kaplan–Meier
(KM) method, and log-rank test was done to compare sur-
vival distribution between groups. Multivariable analysis
was performed by Cox proportional hazards model.
P < 0.05 (two-sided) was considered statistically significant.
Results
Samples and clinical data
A summary of clinical features of this study cohort is shown
in Table 1. A total of 67 IDH-mutant primary glioblastoma
samples were collected in this study. MRI studies showed
37/42 cases (88.1%) with enhancement on T1 but the
imaging records of 25 cases were no longer available for
review. For histological review, all cases showed variable
degrees of hypercellularity and cellular anaplasia. All
except 3 cases showed necrotic foci and 43 cases showed
microvascular proliferation, including the 3 cases without
necrosis. Male-to-female ratio was 1.6:1. The mean and
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median age at diagnosis were 39.3 years old and 38.0 years
old, respectively. Most patients received gross total resec-
tion (56/67; 83.6%). Most patients (n= 50; 74.6%) were
given both chemotherapy and radiotherapy. Radiotherapy
alone was given to 2 (3.0%) patients. Follow-up data for
overall survival (OS) and progression-free survival (PFS)
were available for 64 and 57 cases, respectively. The mean
and median follow-up periods were 58.9 months and
60.1 months, respectively. Median OS was 39.4 months,
with a 2-year survival of 64.1% and a 5-year survival of
30.8%. Median PFS was 25.9 months. Univariate Cox
regression was performed according to the clinical features,
including gender, age at diagnosis, tumour location,
operation, chemotherapy and radiotherapy (Supplementary
Table 1). Only being female was significantly associated
with a better PFS (p= 0.011). Age had no correlation with
survival (OS: p= 0.297; PFS: p= 0.769).
IDH-mutant primary glioblastomas had a better
prognosis than IDH-wildtype glioblastomas and IDH-
mutant secondary glioblastomas
Our cohort of IDH-mutant primary glioblastomas showed a
median OS of 39.4 months and median PFS of 25.9 months.
This was a longer median OS than IDH-wildtype glio-
blastomas (13.6 months, p < 0.001, log-rank test; Fig. 1A)
as we could retrieve from established databases [24, 25] and
IDH-mutant secondary glioblastomas (18.8 months, p=
0.032, log-rank test; Fig. 1C) as we could retrieve from Hu
et al. [12]. Our cohort also had a longer median PFS than
IDH-wildtype glioblastomas (8.7 months, p < 0.001, log-
rank test; Fig. 1B) as in established databases [24, 25] and
IDH-mutant secondary glioblastomas (11.3 months, p=
0.002, log-rank test; Fig. 1D) as in Hu et al. [12].
Classification of G-CIMP groups based on genome-
wide DNA-methylation profiling
We determined genome-wide DNA-methylation profiling in
53 IDH-mutant primary glioblastomas with sufficient tissue
material for Illumina MethylationEPIC (850k) arrays. We
applied RF with a two-step process and assigned the sam-
ples into one of the two IDH-mutant methylation-based
glioma subgroups (G-CIMP-high and G-CIMP-low)
according to the previous publication [15]. The majority of
the samples belonged to G-CIMP-high group (36/53;
67.9%), and G-CIMP-low was present in 17/53 (32.1%) of
cases. As described below, G-CIMP-low tumours were
associated with PDGFRA amplification (p= 0.005). The
correlations between G-CIMP-low and PDGFRA mutation,
and between G-CIMP-low and TP53 mutation were not
quite significant (p= 0.060 and p= 0.056, respectively)
(also see the section Targeted Sequencing below).
DNA methylomes clustered with two main DNA-
methylation classes
We then conducted an unsupervised clustering of our
samples using the reference cohorts and classes of the
Table 1 Clinical data summary.




Age at diagnosis (years old)
Mean ± SD 39.3 ± 12.2
Median 38.0
Tumour location: lobular involvement
Unilobular 52 (77.6%)
Multilobular 8 (11.9%)
Involvement of non-lobular areas 7 (10.4%)
Tumour location: lobe
Frontal lobe 48 (71.6%)
Temporal lobe 16 (23.9%)
Parietal lobe 4 (6.0%)




Not enhanced 5 (7.5%)
Unknown 25 (37.3%)
Operation
Gross total resection 56 (83.6%)




No adjuvant therapy 11 (16.4%)
Chemotherapy only 0 (0%)
Radiotherapy only 2 (3.0%)






Overall survival (months, Kaplan–Meier)
Median (95% CI) 39.4 (24.6–54.2)
2-year survival 64.1%
5-year survival 30.8%
A summary of clinical features of our cohort of IDH-mutant primary
glioblastomas.
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German Cancer Research Centre (DKFZ) as per Capper
et al. [17], and also using the method of t-SNE dimen-
sionality reduction as per that paper. As shown in Fig. 2,
with the exception of one case, all samples were clustered or
in close proximity to either the methylation class called IDH
glioma, subclass astrocytoma (A_IDH) or the methylation
class called IDH glioma, subclass high-grade astrocytoma
(A_IDH_HG). With the DBSCAN algorithm described
previously [26], the majority of our cohort were annotated
to IDH glioma, subclass high-grade astrocytoma (40/53;
75.5%), and 12/53 cases (22.6%) were annotated to IDH
glioma, subclass astrocytoma. There was one outlier clus-
tered in proximity to the DKFZ classifier glioblastoma, IDH
wildtype, subclass mesenchymal but Sanger sequencing and
targeted sequencing both confirmed an IDH1-R132H
mutation for this case. A review of the histology confirmed
regular features of glioblastomas and the H&E of this case
is provided in Supplementary Fig. 1. In view of the t-SNE
findings, we evaluated histologically all the cases desig-
nated to the methylation class IDH glioma, subclass astro-
cytoma (A_IDH) and confirmed that the cases satisfied
WHO 2016 histological criteria for glioblastomas. Repre-
sentative photomicrographs from these cases showing
necrotic foci are included in Supplementary Fig. 2. In spite
of the cohorts being IDH-mutant, no case was clustered
with 1p19q codeleted oligodendroglioma class.
Korshunov et al. studied 97 IDH-mutant glioblastomas,
which included both primary and secondary tumours, by
450k methylation array. They selected the 10 000 most
variably methylated CpG probes for unsupervised hier-
archical clustering [3]. The results showed 84/97 cases
(86.6%) clustered to IDH-mutant high-grade glioma and
11/97 cases (11.3%) to IDH-mutant astrocytoma class. They
also had the odd outliers similar to us.
We then correlated the DNA-methylation classes to G-
CIMP status. We found a strong correlation between
Fig. 1 IDH-mutant primary
glioblastomas show better OS
and PFS than IDH-wildtype
glioblastomas and IDH-
mutant secondary
glioblastomas. A OS and B PFS
of IDH-mutant primary
glioblastomas in this study and
IDH-wildtype glioblastomas
from established databases
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G-CIMP status and DNA-methylation class in IDH-mutant
glioblastomas (p= 0.017; Supplementary Table 2). G-
CIMP-low tumours (17/17) were clustered or near the IDH
glioma, subclass high-grade astrocytoma (A_IDH_HG). All
tumours clustered to IDH glioma, subclass astrocytoma
(A_IDH) were G-CIMP-high tumours. However, DNA-
methylation classes were not associated with OS (p= 0.104)
and PFS (p= 0.181) in our cohort. Methylation classes were
also not associated with CDKN2A/B deletion, PDGFRA
amplification, and TP53 mutation (see below). MGMT pro-
moter methylation status can be derived directly from the
methylation profiling [17, 27]. Overall, 46/53 (86.8%) cases
were found to be MGMT promoter methylated. MGMT
promoter methylation was not associated with G-CIMP
status or methylation classes.
Copy number variation analysis showed significant
differences from IDH-wildtype glioblastomas
A summary of the molecular findings in this cohort, toge-
ther with copy number variations (CNVs) is depicted in
Fig. 3.
CNVs were found to be extremely useful derivatives of
DNA-methylation profiles in gliomas [9, 28]. We thus
determined CNVs from EPIC 850k array data according to
previous research [17]. We employed GISTIC analysis to
determine statistically significant recurrent amplifications
and losses at arm-level and focal-level. At the arm-level, we
found that the IDH-mutant primary glioblastomas showed
significant amplification at chromosomes 8q, 10p, and 12p
and significant loss at chromosomes 3p, 4q, 9p, 10p, 10q,
11p, 13q, 14q, and 19q (Fig. 4A; q < 0.05). At focal-level,
we found recurrent amplification regions on chromosomes
4q12, 8q24.21, 11q13.3, 11q14.1, 12p13.32, 12q14.1 and
13q33.3. Genes located in these regions include PDGFRA,
MYC, CCND1, CCND2, and CDK4 (Fig. 4B). We also
identified eight recurrent loss regions and they were on
chromosomes 4q35.1, 5q34, 6p21.32, 8p23.3, 9p21.3,
10q26.3, 11p15.4, and 13q14.2. Genes located in these
regions included the well-known CDKN2A and CDKN2B.
Chromosome 7 gain and chromosome 10 loss are molecular
hallmark of many glioblastomas, and cIMPACT-NOW 3
recommended that IDH-wildtype diffuse astrocytic glioma
with their combined whole chromosome loss would follow
an aggressive clinical course closely resembling that of an
IDH-wildtype glioblastoma despite their grade II or III
histology [29]. Thus, we in particular determined the fre-
quency of +7/−10 in our cohort and found that only 4/53
cases (7.5%) had +7/−10.
At gene-level, we investigated genes with established
relevance in gliomas [9]. We employed the cutoff estab-
lished in Shirahata et al. study to determine amplification
and deletion. The results revealed that EGFR amplification
which is frequently found in the regular glioblastomas was
infrequent in our cohort (6/53; 11.3%). Instead, in our
cohort, we detected amplifications of CDK4 (15/53; 28.3%),
CCND2 (12/53; 22.6%), ERBB2 (11/53; 20.8%), MYC (10/
53; 18.9%), MET (9/53, 17.0%) PDGFRA (8/53; 15.1%),
Fig. 2 Unsupervised clustering of reference cohort samples and 53
IDH-mutant primary glioblastomas using t-SNE dimensionality
reduction. The reference cohort of the DKFZ CNS tumour classifier
includes 82 tumour and 9 non-tumour classes and they are shown as
circles of different colours. Except one case, all IDH-mutant primary
glioblastomas in this study (shown in red triangle or green diamond)
clustered close to the methylation class called IDH glioma, subclass
astrocytoma (A_IDH) or IDH glioma, subclass high-grade astrocytoma
(A_IDH_HG). Mutations of IDH in our samples were tested and
confirmed by independent PCR and Sanger sequencing.
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and PIK3CA (2/53; 3.8%). PTEN deletion was identified in
6/53 cases (11.3%), and homozygous deletion of CDKN2A/
B was identified in 23/53 cases (43.4%) (Table 2). In our
cohort, we did not observe a difference in EGFR promoter
methylation between EGFR amplified and non-amplified
cases (p= 0.388).
When compared with IDH-wildtype glioblastomas in
TCGA databases [24, 25], our cohort had much fewer
Fig. 3 Summary of the clinical and molecular characteristics of
IDH-mutant primary glioblastomas. The top black bar chart repre-
sents the OS of each sample in months. The coloured bar chart on the
right represents the frequency of tumours with the genetic and
genomic aberrations found in this study. The bottom black bar chart
indicates the number of mutations in each tumour identified by tar-
geted sequencing. The central heatmap illustrates the molecular
alterations. Each column represents one sample.
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EGFR amplifications (11.3% vs. 43.2%). Our cohort how-
ever showed more amplifications of CCND2 (22.6% vs.
2.1%), ERBB2 (20.8% vs. 0%), MYC (18.9% vs. 1.2%), and
MET (17.0% vs. 4.0%). Similarly, some of the other genetic
alterations mentioned by the cIMPACT-NOW update 5 to
possibly be important in the pathogenesis of IDH-mutant
Fig. 4 Significant CNVs identified by GISTIC 2.0. A Significant
arm-level CNVs in IDH-mutant primary glioblastomas. Frequencies of
CNVs are shown on the x-axes, while the human chromosomes 1–22
are illustrated along the y-axis. Arms with significant alterations (q <
0.05) are marked with an asterisk. Data on 13p, 14, 15p and 22p are
not shown and were not significant. B Significant focal-level CNVs in
IDH-mutant primary glioblastomas. Statistical significance of CNVs is
indicated by false discovery rate Q values on the x-axes.
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astrocytoma, Grade IV, were not very common in our IDH-
mutant primary glioblastomas: deletion of RB1 (9/53;
17.0%), amplification of MYCN (4/53; 7.5%), and deletion
of PIK3R1 (3/53; 5.7%). No case displayed 1p19q
codeletion.
In G-CIMP-low tumours (n= 17), we identified sig-
nificant PDGFRA amplification (p= 0.005). G-CIMP status
was not associated with other CNVs.
We also computed the frequency of CNVs in our cohort
by established method [30, 31]. We found that G-CIMP
high group had a significantly lower frequency of CNVs
compared to the G-CIMP low group (p= 0.013; 4.43%
+/− 4.51% vs. 8.37% +/− 6.46%).
Gene fusion was very rare in IDH-mutant primary
glioblastomas
RNA sequencing was performed on 41 IDH-mutant primary
glioblastomas in our cohort with sufficient materials. Sur-
prisingly, only 4 intrachromosomal fusions were detected in
2/41 (4.9%) cases. The fusion genes were PTPRZ1-MET,
UBTD2-CSF1R, SARNP-MYL2 and LRP1-TRHDE. One
tumour carried three fusion genes. The PTPRZ1-MET
fusion gene was identified in 1/41 (2.0%) cases and the
same fusion was also found by Hu et al. in secondary
glioblastomas [12]. All four fusion genes were confirmed by
RT-PCR and Sanger sequencing (Fig. 3; Supplementary




Type of CNA Frequency
(n= 53)
Percentage p value (OS) p value (PFS)
CDK4 Amplification 15 28.30% 0.640 0.359
CCND2 Amplification 12 22.60% 0.704 0.664
ERBB2 Amplification 11 20.80% 0.738 0.601
MYC Amplification 10 18.90% 0.205 0.137
MET Amplification 9 17.00% 0.841 0.960
PDGFRA Amplification 8 15.10% 0.489 0.871
EGFR Amplification 6 11.30% 0.663 0.197
CDK6 Amplification 5 9.40% 0.940 0.674
MDM4 Amplification 5 9.40% 0.798 0.747
KRAS Amplification 4 7.50% 0.357 0.750
MYCN Amplification 4 7.50% 0.577 0.709
CCND1 Amplification 3 5.70% 0.290 0.501
MDM2 Amplification 2 3.80% 0.609 0.170
PIK3CA Amplification 2 3.80% 0.398 0.142
PPM1D Amplification 1 1.90% 0.270 0.271
FGFR1 Amplification 0 0.00% N/A N/A
FGFR3 Amplification 0 0.00% N/A N/A
CDKN2A/B Homozygous
deletion
23 43.40% 0.197 0.278
CDKN2A Homozygous
deletion
16 30.20% 0.290 0.138
CDKN2B Homozygous
deletion
22 41.50% 0.077 0.097
RB1 Homozygous
deletion
9 17.00% 0.488 0.290
PTEN Homozygous
deletion
6 11.30% 0.404 0.750
PIK3R1 Homozygous
deletion
3 5.70% 0.779 0.830
NF1 Homozygous
deletion
1 1.90% 0.585 N/A
14q Homozygous
deletion
5 9.40% 0.822 0.816
N/A data not available.
Frequency of copy number alterations (CNAs) and their correlations with OS and PFS.
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Fig. 3). The fact that gene fusion was a rare event in our
cohort is different from what was found in glioblastomas in
general where gene fusions are abundant and fusion genes
are potential targets for therapy [32–34].
Targeted sequencing showed differences from IDH-
wildtype glioblastomas and IDH-mutant secondary
glioblastomas
Targeted next-generation sequencing was performed on
53 samples in our cohort using an in-house panel which
contains 74 genes relevant to the pathogenesis of brain
tumours (Supplementary Table 3). Overall, there are 7.98 ±
4.57 mutations/sample. All mutations are listed in Supple-
mentary Table 4. Sanger sequencing was used to identify
TERT promoter mutations in 67 samples. The most sig-
nificant finding was the extremely low occurrence of TERT
promoter mutation (2/67; 3.0%). Both TERT promoter
mutations found were C228T. Other mutations that were,
interestingly, rarely found in our cohort were EGFR (2/53;
3.8%) MET (4/53; 7.5%), FGFR3 (5/53; 9.4%), and PTEN
(2/53; 3.8%). Another significant finding was the high
incidence of ATRX (34/53; 64.2%) and TP53 (30/53,
56.6%) mutations (Table 3). Other recurrent mutations in
our cohort included KMT2D (18/53; 34.0%), FAT1 (14/53;
26.4%), POLE (12/53; 22.6%), KMT2C (11/53; 20.8%),
PTCH1 (11/53; 20.8%), PIK3CA (11/53; 20.8%), and
PDGFRA (10/53; 18.9%). DNA mismatch repair (MMR)
genes were mutated in a small proportion of cases (11
cases) including MSH6 (8/53; 15.1%), MSH2 (2/53; 3.8%),
PMS2 (2/53, 3.8/%), and MLH1 (1/53; 1.9%). All except
two cases showed only single MMR mutation. For these
two cases, one tumour had mutations of the MSH2 and
PMS2 while another had mutations of MSH2 and MSH6.
Germline DNA was not available for testing. No prior
chemotherapy was given as these were primary tumours
with first presentations.
When compared with IDH-wildtype primary glio-
blastomas in the literature [35], our cohort of IDH-mutant
primary glioblastomas showed very few TERT promoter
mutations (3.0% vs. 80.4%). When compared with IDH-
wildtype glioblastomas in TCGA databases [24, 25], our
cohort also showed more mutations in ATRX (64.2% vs.
0%), TP53 (56.6% vs. 7.1%), KMT2D (34.0% vs. 0.4%),
FAT1 (26.4% vs. 0.4%), POLE (22.6% vs. 0.1%), PDGFRA
(18.9% vs. 1.8%), and MSH6 (15.1% vs. 0.4%). When
compared with IDH-mutant secondary glioblastomas in
literature [12], our samples had more mutations in PDGFRA
(18.9% vs. 5.2%) but fewer TP53 mutations (56.6% vs.
80%). Supplementary Table 5 summarizes the prevalence of
genetic and genomic alterations among IDH-mutant pri-
mary glioblastomas, IDH-wildtype glioblastomas, and IDH-
mutant secondary glioblastomas. We identified cases as
suggestive of hypermutation when the number of mutations
was greater than the mean+2 S.D [36]. Three cases in this
cohort displayed a potential hypermutation state (3/53;
5.7%), and the frequency is lower than that in IDH-mutant
secondary glioblastomas (5.7% vs. 18.6%) [12]. Two of the
three potentially hypermutated cases incidentally also
showed MSH6 mutation as described above. Given the facts
that the size of our target panel was relatively small cov-
ering 74 genes and we lacked tissue materials, we could not
further confirm hypermutation status. The two other genes
mentioned by cIMPACT-NOW update 5 [11] as having
possible pathogenetic significance in IDH-mutant astro-
cytoma, Grade IV, were as follows: PIK3CA was mutated in
11/53 (20.8%) cases, and PIK3R1 was mutated in 4/53
(7.5%) cases.
Canonical pathways altered in IDH-mutant primary
glioblastomas
Three canonical pathways are well known to be aberrated in
glioblastomas, namely RTK/RAS/PI3K/AKT pathway,
TP53 pathway, and RB pathway. When we combined copy
number variation analysis with targeted sequencing results,
RTK/RAS/PI3K/AKT pathway was altered in 67.2% sam-
ples, with PDGFRA aberrations being the most common
(27%) (Fig. 5). TP53 pathway was altered in 59.7%
Table 3 Survival analysis of gene mutations.
Gene Frequency
(n= 53)
Percentage p value (OS) p value (PFS)
ATRX 34 0.642 0.524 0.681
TP53 30 0.566 0.020 0.331
KMT2D 18 0.340 0.337 0.217
FAT1 14 0.264 0.296 0.871
POLE 12 0.226 0.395 0.28
KMT2C 11 0.208 0.793 0.439
PIK3CA 11 0.208 0.274 0.774
PTCH1 11 0.208 0.108 0.222
PDGFRA 10 0.189 0.279 0.278
KMT2B 9 0.170 0.123 0.072
NOTCH1 9 0.170 0.787 0.867
ROS1 9 0.170 0.094 N/A
SPTA1 9 0.170 0.741 0.148
MSH6 8 0.151 0.637 0.899
SETD2 8 0.151 0.364 0.422
NF1 7 0.132 0.100 0.907
CIC 6 0.113 0.643 0.614
FGFR3 5 0.094 0.295 0.802
KEL 5 0.094 0.797 0.884
N/A data not available.
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samples, with TP53 aberrations being the most common
(53%). RB pathway was altered in 65.7% samples, with
CDKN2B deletion being the most common (42%). The
proportions of all three were lower than those observed in
IDH-wildtype glioblastomas as retrieved from TCGA:
RTK/RAS/PI3K/AKT (90%), TP53 (86%) and RB (79%)
pathways [24]. Two other pathways significantly involved
in the pathogenesis of IDH-mutant primary glioblastomas
included chromatin modifiers (88.7%) and DNA mismatch
repair genes (20.8%). The former’s high level of involve-
ment was due to the frequent mutations of ATRX as men-
tioned above. The alteration of signalling pathways in this
cohort of IDH-mutant primary glioblastomas is depicted in
Fig. 5.
Clinical correlations of molecular parameters
G-CIMP-high tumours showed a significantly longer OS
than G-CIMP-low ones (median: 44.5 months vs.
24.7 months, p= 0.015, log-rank test; Fig. 6A). G-CIMP-
high tumours also displayed a trend towards longer PFS
compared to the G-CIMP-low tumours (Fig. 6B). MGMT
promoter methylation was correlated with a better OS (p=
0.001) and a better PFS (p= 0.042) (Fig. 6C, D).




DNA mismatch repair genes,
RTK/RAS/PI3K/AKT pathway,
TP53 pathway, and RB
pathway.
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TP53 mutation was correlated with a worse OS
(p= 0.020; Fig. 6E) but not PFS (p= 0.331; Fig. 6F). It is
the only major pathogenetic gene of which mutation or copy
number alteration was correlated with survival. Also,
PIK3R1 amplification showed a trend toward poor overall
survival (p= 0.079).
In multivariate analysis, G-CIMP-high subgroup
(p= 0.022; Supplementary Table 6A) and MGMT promoter
methylation (p= 0.002; Supplementary Table 6B) were
both independent prognostic factors for better OS. TP53
mutation was an independent poor prognosticator for OS
(p= 0.013) (Supplementary Table 6C).
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Correlation with OS and PFS of other major genetic
aberrations, including copy number alterations and muta-
tions, is depicted in Tables 2 and 3. Only genetic events
with significant hits are included. Details can also be
referred to Fig. 3. None of the following genes or chro-
mosomal arms which were discussed in previous publica-
tions as of potential pathogenetic significance in IDH-
mutant gliomas was correlated with survival: ATRX, CDK4,
MET, MYCN, PIK3R1, or 14q [10, 11, 36]. Frequency of
CNVs was also not correlated with survival (OS: p= 0.645;
PFS: p= 0.598).
Among IDH-mutant glioblastomas including both pri-
mary and secondary glioblastomas, two studies including
ours concluded that CDKN2A was a marker for poor
prognosis [3, 4]. Both studies included secondary glio-
blastomas in the cohorts. However, in our cohort where
only IDH-mutant primary glioblastomas were studied,
homozygous deletion of CDKN2A interestingly was not
correlated with OS (p= 0.290) and PFS (p= 0.138)
(Table 2). CDKN2B homozygous deletion showed a trend
of poor OS (p= 0.077) and PFS (p= 0.097) (Table 2).
Deletion of CDKN2A/B was not correlated with OS (p=
0.197) or PFS (p= 0.278) (Supplementary Fig. 4A, B).
Discussion
This study showed that IDH-mutant primary glioblastomas
had a better survival than the more common IDH-wildtype
glioblastomas as retrieved from the TGCA datasets [24, 25].
While this is as expected, as a matter of fact, the number of
IDH-mutant glioblastomas with survival data as examined
by Yan et al. in their seminal paper was only 14 [2]. Since
then there have been only been three sizeable series of IDH-
mutant glioblastomas [3–5]. Two of these series [3, 4]
contained both primary and secondary IDH-mutant glio-
blastomas and the situation is uncertain for the other [5].
And the former two conducted more extensive character-
ization than the latter. Our present cohort, while overlapping
with one of the previous series [4], contained only primary
tumours with the secondary tumours removed. Additional
new cases of IDH-mutant primary glioblastomas have been
added to the series in our present study. Secondary glio-
blastomas were already extensively investigated by Hu et al.
for molecular landscape [12] and they found MET-exon
14 skipping (METex14) as a potential therapeutic target for
secondary glioblastomas. Interestingly, our cohort showed
for the first time that primary glioblastomas, when they
were of the IDH-mutant genotype, had a better prognosis
than IDH-mutant secondary glioblastomas as documented
by Hu et al. This corroborates the clinical findings that IDH-
mutant diffuse astrocytomas, once they progress pre-
sumably with many becoming high-grade gliomas, will
become aggressive [13]. This may be due to the fact that
most Grades 2–3 astrocytomas would have been treated
with chemoradiotherapy before progressing to glio-
blastomas and studies have demonstrated that IDH-mutant
cells can undergo clonally expansion to obtain growth
advantage and post-treatment mutant gliomas responded to
PD-1 blockade poorly [37, 38]. Our study is the largest
single series of IDH-mutant glioblastoma to our knowledge.
In this study, although the prognosis of IDH-mutant
primary glioblastomas was relatively good compared with
the regular glioblastomas, with a median OS of 39.4 months
and a 5-year survival of only 30.8%, it was still not a low-
grade tumour. The prognosis we showed in this cohort was
still much worse than the prognosis of low-grade IDH-
mutant astrocytomas as recorded in the literature [9, 10, 30].
However, it is possible that some IDH-mutant primary
glioblastomas may be molecularly akin to IDH-mutant
astrocytoma and similar clustering was also observed by
Korshunov et al. [3]. It is hard to be certain whether intra-
tumoral heterogeneity and regional variation of molecular
changes among tumour clones have affected the results of
ours and Korshunov’s [3]. But our genome-wide DNA-
methylation analysis also showed that many G-CIMP-high
cases were clustered to the IDH-mutant astrocytoma
methylation class. Furthermore, G-CIMP-high tumours
were associated with a favourable outcome and G-CIMP
subgroups and MGMT promoter methylation were inde-
pendent favourable prognosticators for overall survival.
Surprisingly, fusion genes were identified in only two
cases in this study. This is in contrast to the common fusion
events involving genes like EGFR, FGFR3, MET, and
NTRK1/2/3 in glioblastomas [24, 32, 33]. IDH-mutant pri-
mary glioblastomas showed extensive differences from
IDH-wildtype glioblastomas. The most significant findings
were that the key molecular markers for the diagnosis of the
common glioblastoma, namely EGFR amplification or
mutation, 10q loss or PTEN mutation, and TERT promoter
mutation, were rare in IDH-mutant primary glioblastomas
[24, 25, 35]. Like us, Korshunov et al. also found only a
very small number of cases with TERT promoter mutations
in their series [3]. Telomere maintenance seemed to be done
via the alternative lengthening of telomeres (ALT)
mechanism with a high percentage of ATRX mutation
(64.2%) [39–41]. ATRX mutations are known to be asso-
ciated with IDH-mutant gliomas [42, 43]. Very sig-
nificantly, EGFR amplification, combined 7+/10− and
TERT promoter mutation [11, 44, 45] were only found in 6/
53 (11.3%), 4/53 (7.5%), and 2/67 (3.0%) cases, respec-
tively, in our cohort.
The three well-known pathways involved in glio-
blastoma pathogenesis, namely RTK/RAS/PI3K/AKT,
TP53, and RB pathways, were involved to a lesser extent in
our cohort when compared with TCGA [25] while
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mismatch repair genes and chromatin modifying pathways
were significantly involved. The latter was involved in a
majority of cases because of the high incidence of ATRX
mutation, suggesting that IDH-mutant primary glio-
blastomas make use of the ALT (alternative lengthening for
telomeres) mechanism for telomere maintenance instead of
TERT promoter mutation [38, 40]. For the mismatch repair
genes, their mutations did not seem to lead onto hypermu-
tations as can be seen in other gliomas with mutations of
these genes [38, 46].
cIMPACT-NOW update 5 proposed CDKN2A/B dele-
tion to be a diagnostic marker for IDH-mutant astrocytoma
IV/IDH-mutant glioblastoma [11] and two studies examin-
ing IDH-mutant glioblastomas, inclusive of both primary
and secondary tumours, concluded CDKN2A deletion as a
prognosticator for this group of tumours [3, 4]. Our findings
were consistent with the cIMPACT-NOW’s proposal to use
CDKN2A/B deletion as a diagnostic criteria for an IDH-
mutant astrocytoma being Grade IV, as this was found in
43.4% of this series. G-CIMP subgroup and MGMT pro-
moter methylation were independent good prognosticators
and TP53 mutation was an independent poor prog-
nosticator. MGMT promoter methylation has been an
established prognosticator for glioblastoma [47, 48] and
Ceccarelli et al. have shown the utility of G-CIMP status in
the prognostication of IDH-mutant gliomas though their
series consisted mostly of lower grade IDH-mutant gliomas
[15]. Our findings showed that in IDH-mutant primary
glioblastoma itself, prognostication should be based on G-
CIMP subgroup, MGMT promoter methylation, and TP53
mutation instead of relying on CDKN2A homozygous
deletion alone. Clinical management of IDH-mutant pri-
mary glioblastomas which are G-CIMP-low or MGMT
promoter unmethylated or TP53 mutated should take into
consideration of the poorer prognosis of these tumours in
spite of their mutant IDH genotype. Figure 7 depicts the
prognostic significance of molecular features identified in
this study.
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